z-logo
open-access-imgOpen Access
Japanese guidelines for childhood asthma 2017
Author(s) -
Hirokazu Arakawa,
Yuhei Hamasaki,
Yoichi Kohno,
Motohiro Ebisawa,
Naomi Kondo,
Sankei Nishima,
Toshiyuki Nishimuta,
Akihiro Morikawa
Publication year - 2017
Publication title -
allergology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.49
H-Index - 58
eISSN - 1440-1592
pISSN - 1323-8930
DOI - 10.1016/j.alit.2016.11.003
Subject(s) - guideline , medicine , asthma , asthma management , allergy , pediatrics , intensive care medicine , leukotriene , disease management , intervention (counseling) , family medicine , disease , immunology , nursing , pathology , parkinson's disease
The Japanese Guideline for the Diagnosis and Treatment of Allergic Diseases 2017 (JAGL 2017) includes a minor revision of the Japanese Pediatric Guideline for the Treatment and Management of Asthma 2012 (JPGL 2012) by the Japanese Society of Pediatric Allergy and Clinical Immunology. The section on child asthma in JAGL 2017 provides information on how to diagnose asthma between infancy and adolescence (0-15 years of age). It makes recommendations for best practices in the management of childhood asthma, including management of acute exacerbations and non-pharmacological and pharmacological management. This guideline will be of interest to non-specialist physicians involved in the care of children with asthma. JAGL differs from the Global Initiative for Asthma Guideline in that JAGL emphasizes diagnosis and early intervention of children with asthma at <2 years or 2-5 years of age. The first choice of treatment depends on the severity and frequency of symptoms. Pharmacological management, including step-up or step-down of drugs used for long-term management based on the status of asthma control levels, is easy to understand; thus, this guideline is suitable for the routine medical care of children with asthma. JAGL also recommends using a control test in children, so that the physician aims for complete control by avoiding exacerbating factors and appropriately using anti-inflammatory drugs (for example, inhaled corticosteroids and leukotriene receptor antagonists).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom